Table 1. Clinical characteristics of each cohort: age and PSA report median (range), the rest report number n (%). Biopsy gleason grade reports percent of cancers.
| Goeteborg Round 1 | Goeteborg Rounds 2-6 | Rotterdam Round 1 | Rotterdam Rounds 2-3 | Tarn | SABOR | Cleveland Clinic | ProtecT | Tyrol | Durham VA | |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of patients | 740 | 1241 | 2895 | 1494 | 298 | 392 | 2631 | 7324 | 4199 | 1856 |
| Number of biopsies | 740 | 1241 | 2895 | 1494 | 298 | 392 | 3286 | 7324 | 5644 | 2419 |
| Age | ||||||||||
| Median (range) | 61 (51,70) | 63 (53, 71) | 66 (55, 75) | 67 (59, 75) | 64 (55, 71) | 63 (50,75) | 64 (50,75) | 63 (50,72) | 63 (50,75) | 64(50,75) |
| PSA Median | 4.7 | 3.6 | 5.0 | 3.5 | 4.5 | 3.4 | 5.8 | 4.4 | 4.2 | 5.2 |
| Range | (0.5, 226.0) | (2.0, 88.8) | (0.0, 245.0) | (0.4, 99.5) | (1.6, 131.0) | (0.2,919.2) | (0.2,491.7) | (3.0, 847.0) | (0.1,3210.0) | (0.1,1355.6) |
| < 3 ng/mL | 33 (4%) | 205 (17%) | 147 (5%) | 417 (28%) | 26 (9%) | 166 (42%) | 337 (10%) | 0 (0%) | 1614 (29%) | 309 (13%) |
| ≥ 3 ng/mL | 707 (96%) | 1036(83%) | 2748 (95%) | 1077 (72%) | 272 (91%) | 226 (58%) | 2949(90%) | 7324 (100%) | 4030 (71%) | 2110 (87%) |
| DRE result | ||||||||||
| Normal | 614 (83%) | 1117 (90%) | 2137 (74%) | 1182 (79%) | 179 (60%) | 280 (71%) | 3083(94%) | 0 | 5076(90%) | 887(37%) |
| Abnormal | 126 (17%) | 124 (10%) | 758 (26%) | 312 (21%) | 92 (31%) | 112 (29%) | 203 (6%) | 0 | 568 (10%) | 265 (11%) |
| Unknown | 0 | 0 | 0 | 0 | 27 (9%) | 0 | 0 | 7324(100%) | 0 | 1267(52%) |
| Family history | ||||||||||
| No | 0 | 0 | 1708 (59%) | 875 (59%) | 0 | 280 (71%) | 1690(51%) | 5736(78%) | 0 | 0 |
| Yes | 0 | 0 | 328 (11%) | 160 (11%) | 0 | 112 (29%) | 373 (11%) | 454(6%) | 0 | 0 |
| Unknown | 740 (100%) | 1241 (100%) | 859 (30%) | 459 (31%) | 298 (100%) | 0 | 1223(37%) | 1134(15%) | 5644(100%) | 2419(100%) |
| African origin | ||||||||||
| No | 0 | 0 | 0 | 0 | 0 | 349 (89%) | 2818(86%) | 6933(95%) | 0 | 1218(50%) |
| Yes | 0 | 0 | 0 | 0 | 0 | 43 (11%) | 422 (13%) | 34 (0%) | 0 | 1079(45%) |
| Unknown | 740 (100%) | 1241 (100%) | 2895 (100%) | 1494 (100%) | 298 (100%) | 0 | 46 (1%) | 357 (5%) | 5644(100%) | 122 (5%) |
| Prior biopsy | ||||||||||
| Yes | 0 | 0 | 0 | 0 | 0 | 96(24%) | 1091(33%) | 0 | 1555(28%) | 568(23%) |
| No | 740(100%) | 1241(100%) | 2895(100%) | 1494(100%) | 298(100%) | 296(76%) | 2195(67%) | 7324(100%) | 4089(72%) | 1851(77%) |
| Cancer | 192 (26%) | 322 (26%) | 800 (28%) | 388 (26%) | 96 (32%) | 133 (34%) | 1292(39%) | 2570(35%) | 1562 (28%) | 1148(47%) |
| Biopsy Gleason grade | ||||||||||
| ≤ 6 | 152 (79%) | 269 (84%) | 508 (64%) | 297 (77%) | 42 (44%) | 95 (71%) | 669 (52%) | 1703(66%) | 911 (58%) | 606 (53%) |
| 7 | 33 (17%) | 45 (14%) | 234 (29%) | 78 (20%) | 37 (39%) | 28 (21%) | 478 (37%) | 729 (28%) | 319 (20%) | 387 (34%) |
| ≥ 8 | 7 (4%) | 8 (2%) | 52 (6%) | 13 (3%) | 14 (15%) | 7 (5%) | 145 (11%) | 138 (5%) | 137 (9%) | 141 (12%) |
| Unknown | 0 | 0 | 6 (1%) | 0 | 3 (3%) | 3(2%) | 0 | 0 | 195 (12%) | 14(1%) |